Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes

被引:0
|
作者
Rosenzweig, Margaret Quinn [1 ]
Nugent, Bethany [2 ]
McGuire, Meaghan [2 ]
机构
[1] Univ Pittsburgh, Sch Nursing, Nursing, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Pittsburgh, PA USA
关键词
metastatic breast cancer; survival; race; neighborhood; health disparity; NEIGHBORHOOD DEPRIVATION; SURVIVAL; DISPARITIES; INDEX; RACISM; HEALTH;
D O I
10.1188/23.ONF.449-457
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OBJECTIVES: To describe area deprivation, anxiety, depression, relative dose intensity of first-line metastatic breast cancer (MBC) treatment, and survival in Black and White women who had died from triple-negative MBC, including interaction analysis. SAMPLE & SETTING: This cohort study drew from a database of women who had died from MBC (N = 53). METHODS & VARIABLES: Descriptive statistics, independent t tests, analysis of variance, and Mann-Whitney U tests were used, and effect sizes were calculated. RESULTS: Compared with White women, Black women reported higher anxiety and depression at MBC baseline. Black women living in areas of higher deprivation experienced shorter overall survival than White women living in similar areas (9.9 months versus 24.6 months). These results were not statistically significant, likely because of a small sample size, but were clinically meaningful. IMPLICATIONS FOR NURSING: Black and low-income women with breast cancer experience inferior survival as compared with White and higher-income women. Newer explanatory models for racial disparity in cancer outcomes include the assessment of neighborhood deprivation. White women may be less affected by their neighborhood, even when living in areas of greater deprivation influencing cancer outcomes. This merits further exploration.
引用
收藏
页码:449 / 457
页数:9
相关论文
共 50 条
  • [1] Are there differences in outcomes by race among women with metastatic triple-negative breast cancer?
    Oppong, Bridget A.
    Rolle, Angel A.
    Ndumele, Amara
    Li, Yaming
    Fisher, James L.
    Bhattacharyya, Oindrila
    Adeyanju, Toyin
    Paskett, Electra D.
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 196 (02) : 399 - 408
  • [2] Are there differences in outcomes by race among women with metastatic triple-negative breast cancer?
    Bridget A. Oppong
    Angel A. Rolle
    Amara Ndumele
    Yaming Li
    James L. Fisher
    Oindrila Bhattacharyya
    Toyin Adeyanju
    Electra D. Paskett
    Breast Cancer Research and Treatment, 2022, 196 : 399 - 408
  • [3] Metastatic Triple-negative Breast Cancer
    Rakha, E. A.
    Chan, S.
    CLINICAL ONCOLOGY, 2011, 23 (09) : 587 - 600
  • [4] Metastatic Triple-Negative Breast Cancer
    Zhang, Xiaojie
    Yeung, Kay T.
    CURRENT BREAST CANCER REPORTS, 2023, 15 (03) : 288 - 297
  • [5] Metastatic Triple-Negative Breast Cancer
    Xiaojie Zhang
    Kay T. Yeung
    Current Breast Cancer Reports, 2023, 15 : 288 - 297
  • [6] Impact of race on treatment outcomes in triple-negative breast cancer at an academic medical center.
    Patterson, Jasmine
    Meisel, Jane Lowe
    Yi, Sha
    Liu, Yuan
    Cao, Yichun
    Li, Xiaoxian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Does race impact outcomes in triple negative breast cancer?
    Holcomb, K.
    Andrews, J.
    Ensign, L.
    Fields, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S383 - S383
  • [8] Impact of Statin Use on Outcomes in Triple-Negative Breast Cancer
    Shaitelman, S. F.
    Stauder, M. C.
    Allen, P. K.
    Reddy, S.
    Lakoski, S. G.
    Atkinson, B. J.
    Moulder, S.
    Reddy, J.
    Amaya, D.
    Guerra, W.
    Ueno, N. T.
    Caudle, A. S.
    Tereffe, W.
    Woodward, W. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E48 - E48
  • [9] Outcomes for metastatic triple-negative (TN) breast cancer: Impact for clinical practice and trial design
    Kassam, F.
    Enright, K.
    Dent, R.
    Flynn, C.
    Myers, J.
    Fralick, M.
    Kumar, R.
    Clemons, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Atezolizumab for metastatic triple-negative breast cancer
    Stirrups, Robert
    LANCET ONCOLOGY, 2018, 19 (10): : E519 - E519